GLP-1 Adoption Surges: Record Usage, Policy Expansion, and Emerging Management Strategies
Key Questions
How widespread is GLP-1 weight-loss drug use in the US?
Gallup data indicate 11% of Americans are now using these medications, up from 3% in 2024, coinciding with a drop in obesity rates.
Which policy changes are expanding GLP-1 access?
Medicare is introducing a $50/month coverage program, and Wisconsin Medicaid has begun covering GLP-1s for eligible patients.
What safety concerns exist with compounded GLP-1 drugs?
Compounded versions account for 19% of current use and raise safety issues due to variable quality and lack of regulatory oversight.
How might dietary fiber help GLP-1 users?
Emerging research suggests fiber supplementation can reduce GI side effects and potentially limit weight regain during treatment.
Do GLP-1 drugs benefit patients with peripheral artery disease?
Recent data indicate GLP-1 therapies may provide clinical benefits in PAD patients beyond weight loss and glycemic control.
Gallup data shows 11% of Americans now using weight-loss drugs (up from 3% in 2024), with obesity rates dropping. Medicare expands access via $50/month program; Wisconsin Medicaid covers GLP-1s. Compounded drug use at 19% raises safety concerns. New research explores dietary fiber as adjunct to manage GI side effects and weight regain. GLP-1s also show benefit in PAD patients.